Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | DTYMK | P23919 | 1/20 | 0.54 |
| ▸ | DBH | P09172 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825053 | 0.83 | DBH (0.47) | KMT2AMEN1DBHLMNAHPGD | |
| SCHEMBL12410801 | 0.82 | DBH (0.43) | KMT2AMEN1DBHLMNAHPGD | |
| SCHEMBL12410761 | 0.81 | KMT2A (0.46) | KMT2AMEN1DTYMKDBHLMNA | |
| SCHEMBL8022167 | 0.80 | MEN1 (0.66) | KMT2AMEN1DTYMKHPGDALDH1A1 | |
| SCHEMBL12501006 | 0.80 | KMT2A (0.66) | KMT2AMEN1DTYMKCYP1A2CYP2C19 | |
| SCHEMBL1717207 | 0.79 | MEN1 (0.78) | KMT2AMEN1DTYMKCYP1A2CYP2C19 | |
| SCHEMBL12410824 | 0.79 | KMT2A (0.47) | KMT2AMEN1DBHLMNACYP1A2 | |
| SCHEMBL13567219 | 0.78 | KMT2A (0.46) | KMT2AMEN1DBHLMNAHPGD | |
| SCHEMBL17243365 | 0.78 | DBH (0.42) | KMT2AMEN1DBHLMNAHPGD | |
| SCHEMBL7840035 | 0.77 | MEN1 (0.71) | KMT2AMEN1DTYMKCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| WO-2006070292-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1385831-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2002083651-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | KMT2A 1914/4885MEN1 1024/4885DTYMK 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.